AstraZeneca’s shares may have fallen by as much as 6.3% following news of David Brennan’s imminent departure — the biggest intraday decline since December 17, 2010, said Bloomberg — but analysts welcomed his retirement as a good thing. “This will be received positively,” said WestLB’s Mark Belsey. “It’s time for someone to reinvigorate the pipeline.”
With [...]
Brennan Departure: What Now for AZ?